Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 374

1.

Tolerogenic dendritic cell-based treatment for multiple sclerosis (MS): a harmonised study protocol for two phase I clinical trials comparing intradermal and intranodal cell administration.

Willekens B, Presas-Rodríguez S, Mansilla MJ, Derdelinckx J, Lee WP, Nijs G, De Laere M, Wens I, Cras P, Parizel P, Van Hecke W, Ribbens A, Billiet T, Adams G, Couttenye MM, Navarro-Barriuso J, Teniente-Serra A, Quirant-Sánchez B, Lopez-Diaz de Cerio A, Inogés S, Prosper F, Kip A, Verheij H, Gross CC, Wiendl H, Van Ham MS, Ten Brinke A, Barriocanal AM, Massuet-Vilamajó A, Hens N, Berneman Z, Martínez-Cáceres E, Cools N, Ramo-Tello C; RESTORE consortium.

BMJ Open. 2019 Sep 9;9(9):e030309. doi: 10.1136/bmjopen-2019-030309.

2.

Prospective validation of the PML risk biomarker l-selectin and influence of natalizumab extended intervals.

Schwab N, Schneider-Hohendorf T, Pignolet B, Bucciarelli F, Scandella L, Ciron J, Biotti D, Lebrun-Frenay C, Mathey G, Clavelou P, Pelletier J, Ostkamp P, Meinl I, Windhagen S, Klotz L, Gross CC, Meuth SG, Deisenhammer F, Brassat D, Wiendl H; Best-MS Study Group.

Neurology. 2019 Sep 17;93(12):550-554. doi: 10.1212/WNL.0000000000008135. Epub 2019 Aug 22. No abstract available.

PMID:
31439633
3.

Pretreatment anti-thyroid autoantibodies indicate increased risk for thyroid autoimmunity secondary to alemtuzumab: A prospective cohort study.

Ruck T, Schulte-Mecklenbeck A, Pfeuffer S, Heming M, Klotz L, Windhagen S, Kleinschnitz C, Gross CC, Wiendl H, Meuth SG.

EBioMedicine. 2019 Aug;46:381-386. doi: 10.1016/j.ebiom.2019.07.062. Epub 2019 Jul 29.

4.

[Diagnostics and treatment of tuberculosis under immunotherapy for multiple sclerosis : Current status and recommendations in Germany].

Bittner S, Engel S, Lange C, Weber MS, Haghikia A, Luessi F, Korn T, Klotz L, Bayas A, Paul F, Heesen C, Stangel M, Wildemann B, Bergh FT, Tackenberg B, Trebst C, Warnke C, Linker R, Kerschensteiner M, Zettl U, Tumani H, Brück W, Meuth SG, Kümpfel T, Hemmer B, Wiendl H, Gold R, Zipp F.

Nervenarzt. 2019 Jul 11. doi: 10.1007/s00115-019-0760-0. [Epub ahead of print] Review. German.

PMID:
31297574
5.

The next-generation sphingosine-1 receptor modulator BAF312 (siponimod) improves cortical network functionality in focal autoimmune encephalomyelitis.

Hundehege P, Cerina M, Eichler S, Thomas C, Herrmann AM, Göbel K, Müntefering T, Fernandez-Orth J, Bock S, Narayanan V, Budde T, Speckmann EJ, Wiendl H, Schubart A, Ruck T, Meuth SG.

Neural Regen Res. 2019 Nov;14(11):1950-1960. doi: 10.4103/1673-5374.259622.

6.

Low-Frequency and Rare-Coding Variation Contributes to Multiple Sclerosis Risk.

International Multiple Sclerosis Genetics Consortium. Electronic address: chris.cotsapas@yale.edu; International Multiple Sclerosis Genetics Consortium.

Cell. 2019 Jun 27;178(1):262. doi: 10.1016/j.cell.2019.06.016. No abstract available.

7.

A nonsynonymous mutation in PLCG2 reduces the risk of Alzheimer's disease, dementia with Lewy bodies and frontotemporal dementia, and increases the likelihood of longevity.

van der Lee SJ, Conway OJ, Jansen I, Carrasquillo MM, Kleineidam L, van den Akker E, Hernández I, van Eijk KR, Stringa N, Chen JA, Zettergren A, Andlauer TFM, Diez-Fairen M, Simon-Sanchez J, Lleó A, Zetterberg H, Nygaard M, Blauwendraat C, Savage JE, Mengel-From J, Moreno-Grau S, Wagner M, Fortea J, Keogh MJ, Blennow K, Skoog I, Friese MA, Pletnikova O, Zulaica M, Lage C, de Rojas I, Riedel-Heller S, Illán-Gala I, Wei W, Jeune B, Orellana A, Then Bergh F, Wang X, Hulsman M, Beker N, Tesi N, Morris CM, Indakoetxea B, Collij LE, Scherer M, Morenas-Rodríguez E, Ironside JW, van Berckel BNM, Alcolea D, Wiendl H, Strickland SL, Pastor P, Rodríguez Rodríguez E; DESGESCO (Dementia Genetics Spanish Consortium), EADB (Alzheimer Disease European DNA biobank); EADB (Alzheimer Disease European DNA biobank); IFGC (International FTD-Genomics Consortium), IPDGC (The International Parkinson Disease Genomics Consortium); IPDGC (The International Parkinson Disease Genomics Consortium); RiMod-FTD (Risk and Modifying factors in Fronto-Temporal Dementia); Netherlands Brain Bank (NBB), Boeve BF, Petersen RC, Ferman TJ, van Gerpen JA, Reinders MJT, Uitti RJ, Tárraga L, Maier W, Dols-Icardo O, Kawalia A, Dalmasso MC, Boada M, Zettl UK, van Schoor NM, Beekman M, Allen M, Masliah E, de Munain AL, Pantelyat A, Wszolek ZK, Ross OA, Dickson DW, Graff-Radford NR, Knopman D, Rademakers R, Lemstra AW, Pijnenburg YAL, Scheltens P, Gasser T, Chinnery PF, Hemmer B, Huisman MA, Troncoso J, Moreno F, Nohr EA, Sørensen TIA, Heutink P, Sánchez-Juan P, Posthuma D; GIFT (Genetic Investigation in Frontotemporal Dementia and Alzheimer’s Disease) Study Group, Clarimón J, Christensen K, Ertekin-Taner N, Scholz SW, Ramirez A, Ruiz A, Slagboom E, van der Flier WM, Holstege H.

Acta Neuropathol. 2019 Aug;138(2):237-250. doi: 10.1007/s00401-019-02026-8. Epub 2019 May 27.

8.

Seizures and epilepsy in multiple sclerosis: epidemiology and prognosis in a large tertiary referral center.

Langenbruch L, Krämer J, Güler S, Möddel G, Geßner S, Melzer N, Elger CE, Wiendl H, Budde T, Meuth SG, Kovac S.

J Neurol. 2019 Jul;266(7):1789-1795. doi: 10.1007/s00415-019-09332-x. Epub 2019 May 8.

PMID:
31069528
9.

Teriflunomide treatment for multiple sclerosis modulates T cell mitochondrial respiration with affinity-dependent effects.

Klotz L, Eschborn M, Lindner M, Liebmann M, Herold M, Janoschka C, Torres Garrido B, Schulte-Mecklenbeck A, Gross CC, Breuer J, Hundehege P, Posevitz V, Pignolet B, Nebel G, Glander S, Freise N, Austermann J, Wirth T, Campbell GR, Schneider-Hohendorf T, Eveslage M, Brassat D, Schwab N, Loser K, Roth J, Busch KB, Stoll M, Mahad DJ, Meuth SG, Turner T, Bar-Or A, Wiendl H.

Sci Transl Med. 2019 May 1;11(490). pii: eaao5563. doi: 10.1126/scitranslmed.aao5563.

PMID:
31043571
10.

Substance P Saliva Reduction Predicts Pharyngeal Dysphagia in Parkinson's Disease.

Schröder JB, Marian T, Claus I, Muhle P, Pawlowski M, Wiendl H, Suntrup-Krueger S, Meuth SG, Dziewas R, Ruck T, Warnecke T.

Front Neurol. 2019 Apr 16;10:386. doi: 10.3389/fneur.2019.00386. eCollection 2019.

11.

Association of Intrathecal Immunoglobulin G Synthesis With Disability Worsening in Multiple Sclerosis.

Gasperi C, Salmen A, Antony G, Bayas A, Heesen C, Kümpfel T, Linker RA, Paul F, Stangel M, Tackenberg B, Bergh FT, Warnke C, Weber F, Wiendl H, Wildemann B, Zettl UK, Ziemann U, Zipp F, Tumani H, Gold R, Hemmer B; German Competence Network of Multiple Sclerosis.

JAMA Neurol. 2019 Jul 1;76(7):841-849. doi: 10.1001/jamaneurol.2019.0905.

PMID:
31034002
12.

Immune Cell Profiling of the Cerebrospinal Fluid Provides Pathogenetic Insights Into Inflammatory Neuropathies.

Heming M, Schulte-Mecklenbeck A, Brix T, Wolbert J, Ruland T, Klotz L, Meuth SG, Gross CC, Wiendl H, Meyer Zu Hörste G.

Front Immunol. 2019 Mar 21;10:515. doi: 10.3389/fimmu.2019.00515. eCollection 2019.

13.

Risks and risk management in modern multiple sclerosis immunotherapeutic treatment.

Klotz L, Havla J, Schwab N, Hohlfeld R, Barnett M, Reddel S, Wiendl H.

Ther Adv Neurol Disord. 2019 Apr 1;12:1756286419836571. doi: 10.1177/1756286419836571. eCollection 2019. Review.

14.

Prominent T-Cell Responses against the Acetylcholine Receptor ε Subunit in Myasthenia Gravis.

Neuhaus O, Wiesmüller KH, Hartung HP, Wiendl H.

Neurol Res Int. 2019 Mar 3;2019:1969068. doi: 10.1155/2019/1969068. eCollection 2019.

15.

An Assay to Determine Mechanisms of Rapid Autoantibody-Induced Neurotransmitter Receptor Endocytosis and Vesicular Trafficking in Autoimmune Encephalitis.

Amedonu E, Brenker C, Barman S, Schreiber JA, Becker S, Peischard S, Strutz-Seebohm N, Strippel C, Dik A, Hartung HP, Budde T, Wiendl H, Strünker T, Wünsch B, Goebels N, Meuth SG, Seebohm G, Melzer N.

Front Neurol. 2019 Mar 1;10:178. doi: 10.3389/fneur.2019.00178. eCollection 2019.

16.

A fatal case of daclizumab-induced liver failure in a patient with MS.

Stettner M, Gross CC, Mausberg AK, Pul R, Junker A, Baba HA, Schulte-Mecklenbeck A, Wiendl H, Kleinschnitz C, Meuth SG.

Neurol Neuroimmunol Neuroinflamm. 2019 Jan 21;6(2):e539. doi: 10.1212/NXI.0000000000000539. eCollection 2019 Mar. No abstract available.

17.

VLA-2 blockade in vivo by vatelizumab induces CD4+FoxP3+ regulatory T cells.

Breuer J, Schneider-Hohendorf T, Ostkamp P, Herich S, Rakhade S, Antonijevic I, Klotz L, Wiendl H, Schwab N.

Int Immunol. 2019 May 21;31(6):407-412. doi: 10.1093/intimm/dxz018.

PMID:
30783682
18.

Immune Cell Activation in the Cerebrospinal Fluid of Patients With Parkinson's Disease.

Schröder JB, Pawlowski M, Meyer Zu Hörste G, Gross CC, Wiendl H, Meuth SG, Ruck T, Warnecke T.

Front Neurol. 2018 Dec 18;9:1081. doi: 10.3389/fneur.2018.01081. eCollection 2018.

19.

Dietary salt promotes ischemic brain injury and is associated with parenchymal migrasome formation.

Schmidt-Pogoda A, Strecker JK, Liebmann M, Massoth C, Beuker C, Hansen U, König S, Albrecht S, Bock S, Breuer J, Sommer C, Schwab N, Wiendl H, Klotz L, Minnerup J.

PLoS One. 2018 Dec 27;13(12):e0209871. doi: 10.1371/journal.pone.0209871. eCollection 2018.

20.

Plasma kallikrein modulates immune cell trafficking during neuroinflammation via PAR2 and bradykinin release.

Göbel K, Asaridou CM, Merker M, Eichler S, Herrmann AM, Geuß E, Ruck T, Schüngel L, Groeneweg L, Narayanan V, Schneider-Hohendorf T, Gross CC, Wiendl H, Kehrel BE, Kleinschnitz C, Meuth SG.

Proc Natl Acad Sci U S A. 2019 Jan 2;116(1):271-276. doi: 10.1073/pnas.1810020116. Epub 2018 Dec 17.

Supplemental Content

Loading ...
Support Center